NeOnc Technologies Holdings is trading 5.71% up in pre-market at $3.70 after the company confirmed an August 12 presentation of topline Phase 2a NEO100 results in recurrent high-grade glioma.
- The imminent clinical readout is likely outweighing the second-quarter net loss of $14.2 million and sharply higher research spending.
- Management will discuss efficacy, safety, and regulatory next steps during the investor call.